Mazdutide dose guide

Mazdutide dosage

A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. In the phase 3 GLORY-1 trial, people lost about 11% (4 mg) and 14% (6 mg) of their body weight at 48 weeks, and a 9 mg dose averaged about 17% at 60 weeks in GLORY-2. Commonly reported: strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.

Dose range

2–6 mg (research range). Studied in research — not a recommendation.

How often

Weekly

A typical run

Ongoing. Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.

How it’s taken

Vial: SubQ injection

Evidence

Established: Clinical trials or FDA-approved use exists

Half-life

~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)

Mazdutide on your syringe

With a 10 mg vial and 2 mL of water (5 mg in every mL), on a 1 mL (100-unit) U-100 insulin syringe: the low end, 2 mg, is 40 units; and the high end, 6 mg, needs a stronger mix than one syringe holds. 5 doses in the vial at the low end. All U-100: 100 units to the mL. A U-40 syringe reads differently.

Mazdutide in the peptide libraryThe Dose Guide: every peptide

More glp-1 & metabolic peptides

• Semaglutide 0.25–2.4 mg
• Semaglutide (oral) 1.5–25 mg
• Tirzepatide 2.5–15 mg
• Retatrutide 1–12 mg
• Liraglutide 0.6–3 mg
• Dulaglutide 0.75–4.5 mg
• Orforglipron 0.8–17.2 mg
• Survodutide 0.3–6 mg
• Pemvidutide 1.2–2.4 mg
• Cagrilintide 0.25–2.4 mg
• CagriSema 0.25–2.4 mg
• 5-Amino-1MQ 50–100 mg
• SLU-PP-332 250–1000 mcg
• Oxytocin 10–40 IU

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.